{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T16:29:17Z","timestamp":1791304157887,"version":"4.3.1"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000060","name":"U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1 R01 AI41661-01"],"award-info":[{"award-number":["1 R01 AI41661-01"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/s41467-025-60057-0","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T08:05:59Z","timestamp":1751357159000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Divergent antibody recognition profiles are generated by protective mRNA vaccines against Marburg and Ravn viruses"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9704-205X","authenticated-orcid":false,"given":"Michelle","family":"Meyer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8904-9334","authenticated-orcid":false,"given":"Bronwyn M.","family":"Gunn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0759-3983","authenticated-orcid":false,"given":"Colette","family":"Pietzsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandru","family":"Subramani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kritika","family":"Kedarinath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8320-7271","authenticated-orcid":false,"given":"Paula P.","family":"Villarreal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew A.","family":"Hyde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1206-7451","authenticated-orcid":false,"given":"Erica Ollmann","family":"Saphire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0049-1079","authenticated-orcid":false,"suffix":"Jr.","given":"James E.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7680-9215","authenticated-orcid":false,"given":"Galit","family":"Alter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7954-9674","authenticated-orcid":false,"given":"Sunny","family":"Himansu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5508-3809","authenticated-orcid":false,"given":"Andrea","family":"Carfi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0342-4824","authenticated-orcid":false,"given":"Alexander","family":"Bukreyev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,1]]},"reference":[{"key":"60057_CR1","unstructured":"WHO. 2023. Equatorial Guinea confirms first-ever Marburg virus disease outbreak. https:\/\/www.afro.who.int\/countries\/equatorial-guinea\/news\/equatorial-guinea-confirms-first-ever-marburg-virus-disease-outbreak."},{"key":"60057_CR2","unstructured":"WHO. 2023. Tanzania confirms first-ever outbreak of Marburg Virus Disease. https:\/\/www.afro.who.int\/countries\/united-republic-of-tanzania\/news\/tanzania-confirms-first-ever-outbreak-marburg-virus-disease."},{"key":"60057_CR3","unstructured":"WHO. 2021. Marburg virus disease. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/marburg-virus-disease."},{"key":"60057_CR4","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1586\/14760584.7.4.417","volume":"7","author":"DL Swenson","year":"2008","unstructured":"Swenson, D. L. et al. Monovalent virus-like particle vaccine protects guinea pigs and nonhuman primates against infection with multiple Marburg viruses. Expert Rev. Vaccines 7, 417\u2013429 (2008).","journal-title":"Expert Rev. Vaccines"},{"key":"60057_CR5","doi-asserted-by":"publisher","first-page":"e0192312","DOI":"10.1371\/journal.pone.0192312","volume":"13","author":"B Callendret","year":"2018","unstructured":"Callendret, B. et al. A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates. PLoS One 13, e0192312 (2018).","journal-title":"PLoS One"},{"key":"60057_CR6","doi-asserted-by":"publisher","first-page":"94","DOI":"10.3390\/v8040094","volume":"8","author":"JM Dye","year":"2016","unstructured":"Dye, J. M. et al. Virus-like particle vaccination protects nonhuman primates from lethal aerosol exposure with Marburgvirus (VLP vaccination protects macaques against aerosol challenges). Viruses 8, 94 (2016).","journal-title":"Viruses"},{"key":"60057_CR7","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abq6364","volume":"14","author":"R Hunegnaw","year":"2022","unstructured":"Hunegnaw, R. et al. A single-shot ChAd3-MARV vaccine confers rapid and durable protection against Marburg virus in nonhuman primates. Sci. Transl. Med. 14, eabq6364 (2022).","journal-title":"Sci. Transl. Med."},{"key":"60057_CR8","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1128\/CVI.00431-07","volume":"15","author":"DL Swenson","year":"2008","unstructured":"Swenson, D. L. et al. Vaccine to confer to nonhuman primates complete protection against multistrain Ebola and Marburg virus infections. Clin. Vaccin. Immunol. 15, 460\u2013467 (2008).","journal-title":"Clin. Vaccin. Immunol."},{"key":"60057_CR9","doi-asserted-by":"publisher","first-page":"e0010433","DOI":"10.1371\/journal.pntd.0010433","volume":"16","author":"C Woolsey","year":"2022","unstructured":"Woolsey, C. et al. A highly attenuated Vesiculovax vaccine rapidly protects nonhuman primates against lethal Marburg virus challenge. PLoS Negl. Trop. Dis. 16, e0010433 (2022).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"60057_CR10","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nm1258","volume":"11","author":"SM Jones","year":"2005","unstructured":"Jones, S. M. et al. Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. Nat. Med. 11, 786\u2013790 (2005).","journal-title":"Nat. Med."},{"key":"60057_CR11","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.3389\/fimmu.2018.03071","volume":"9","author":"A Marzi","year":"2018","unstructured":"Marzi, A. et al. Protection against Marburg virus using a recombinant VSV-vaccine depends on T and B cell activation. Front Immunol. 9, 3071 (2018).","journal-title":"Front Immunol."},{"key":"60057_CR12","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1473-3099(19)30614-0","volume":"20","author":"DK Clarke","year":"2020","unstructured":"Clarke, D. K. et al. Safety and immunogenicity of a highly attenuated rVSVN4CT1-EBOVGP1 Ebola virus vaccine: a randomised, double-blind, placebo-controlled, phase 1 clinical trial. Lancet Infect. Dis. 20, 455\u2013466 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"60057_CR13","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1016\/S0140-6736(22)02400-X","volume":"401","author":"MJ Hamer","year":"2023","unstructured":"Hamer, M. J. et al. Safety, tolerability, and immunogenicity of the chimpanzee adenovirus type 3-vectored Marburg virus (cAd3-Marburg) vaccine in healthy adults in the USA: a first-in-human, phase 1, open-label, dose-escalation trial. Lancet 401, 294\u2013302 (2023).","journal-title":"Lancet"},{"key":"60057_CR14","doi-asserted-by":"publisher","first-page":"8516","DOI":"10.3390\/ijms25158516","volume":"25","author":"KL O\u2019Donnell","year":"2024","unstructured":"O\u2019Donnell, K. L. et al. Vaccine platform comparison: protective efficacy against lethal Marburg virus challenge in the hamster model. Int. J. Mol. Sci. 25, 8516 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"60057_CR15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1012262","volume":"20","author":"A Flaxman","year":"2024","unstructured":"Flaxman, A. et al. Potent immunogenicity and protective efficacy of a multi-pathogen vaccination targeting Ebola, Sudan, Marburg and Lassa viruse. PLoS Pathog. 20, e1012262 (2024).","journal-title":"PLoS Pathog."},{"key":"60057_CR16","doi-asserted-by":"publisher","first-page":"1610","DOI":"10.1001\/jama.2016.4218","volume":"315","author":"ID Milligan","year":"2016","unstructured":"Milligan, I. D. et al. Safety and immunogenicity of novel adenovirus type 26- and modified vaccinia Ankara-Vectored Ebola vaccines: a randomized clinical trial. JAMA 315, 1610\u20131623 (2016).","journal-title":"JAMA"},{"key":"60057_CR17","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/S1473-3099(20)30476-X","volume":"21","author":"AJ Pollard","year":"2020","unstructured":"Pollard, A. J. et al. Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. Lancet Infect. Dis. 21, 493\u2013506 (2020).","journal-title":"Lancet Infect. Dis."},{"key":"60057_CR18","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1093\/infdis\/jiu511","volume":"211","author":"UN Sarwar","year":"2015","unstructured":"Sarwar, U. N. et al. Safety and immunogenicity of DNA vaccines encoding Ebolavirus and Marburgvirus wild-type glycoproteins in a phase I clinical trial. J. Infect. Dis. 211, 549\u2013557 (2015).","journal-title":"J. Infect. Dis."},{"key":"60057_CR19","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1093\/infdis\/jix592","volume":"217","author":"M Meyer","year":"2018","unstructured":"Meyer, M. et al. Modified mRNA-based vaccines elicit robust immune responses and protect guinea pigs from Ebola virus disease. J. Infect. Dis. 217, 451\u2013455 (2018).","journal-title":"J. Infect. Dis."},{"key":"60057_CR20","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1126\/science.1690918","volume":"247","author":"JA Wolff","year":"1990","unstructured":"Wolff, J. A. et al. Direct gene transfer into mouse muscle in vivo. Science 247, 1465\u20131468 (1990).","journal-title":"Science"},{"key":"60057_CR21","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1016\/S1473-3099(22)00764-2","volume":"23","author":"B Essink","year":"2023","unstructured":"Essink, B. et al. The safety and immunogenicity of two Zika virus mRNA vaccine candidates in healthy flavivirus baseline seropositive and seronegative adults: the results of two randomised, placebo-controlled, dose-ranging, phase 1 clinical trials. Lancet Infect. Dis. 23, 621\u2013633 (2023).","journal-title":"Lancet Infect. Dis."},{"key":"60057_CR22","doi-asserted-by":"publisher","first-page":"1248","DOI":"10.1080\/21645515.2020.1829899","volume":"17","author":"AO Aliprantis","year":"2021","unstructured":"Aliprantis, A. O. et al. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults. Hum. Vaccin Immunother. 17, 1248\u20131261 (2021).","journal-title":"Hum. Vaccin Immunother."},{"key":"60057_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-39376-7","volume":"14","author":"IT Lee","year":"2023","unstructured":"Lee, I. T. et al. Safety and immunogenicity of a phase 1\/2 randomized clinical trial of a quadrivalent, mRNA-based seasonal influenza vaccine (mRNA-1010) in healthy adults: interim analysis. Nat. Commun. 14, 3631 (2023).","journal-title":"Nat. Commun."},{"key":"60057_CR24","unstructured":"FDA US. 2021. FDA Approves First COVID-19 Vaccine. https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-covid-19-vaccine."},{"key":"60057_CR25","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1016\/j.cell.2015.01.031","volume":"160","author":"AI Flyak","year":"2015","unstructured":"Flyak, A. I. et al. Mechanism of human antibody-mediated neutralization of Marburg virus. Cell 160, 893\u2013903 (2015).","journal-title":"Cell"},{"key":"60057_CR26","doi-asserted-by":"publisher","first-page":"13467","DOI":"10.1128\/JVI.01896-12","volume":"86","author":"M Kajihara","year":"2012","unstructured":"Kajihara, M. et al. Inhibition of Marburg virus budding by nonneutralizing antibodies to the envelope glycoprotein. J. Virol. 86, 13467\u201313474 (2012).","journal-title":"J. Virol."},{"key":"60057_CR27","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/j.chom.2020.03.025","volume":"27","author":"PA Ilinykh","year":"2020","unstructured":"Ilinykh, P. A. et al. Non-neutralizing antibodies from a Marburg infection survivor mediate protection by Fc-effector functions and by enhancing efficacy of other antibodies. Cell Host Microbe 27, 976\u2013991 e911 (2020).","journal-title":"Cell Host Microbe"},{"key":"60057_CR28","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1128\/JVI.02172-15","volume":"90","author":"ZY Keck","year":"2016","unstructured":"Keck, Z. Y. et al. Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J. Virol. 90, 279\u2013291 (2016).","journal-title":"J. Virol."},{"key":"60057_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.chom.2017.12.003","volume":"23","author":"LB King","year":"2018","unstructured":"King, L. B. et al. The Marburgvirus-neutralizing human monoclonal antibody MR191 targets a conserved site to block virus receptor binding. Cell Host Microbe 23, 101\u2013109 e104 (2018).","journal-title":"Cell Host Microbe"},{"key":"60057_CR30","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1016\/j.cell.2017.02.017","volume":"168","author":"JM Richner","year":"2017","unstructured":"Richner, J. M. et al. Modified mRNA vaccines protect against Zika virus infection. Cell 168, 1114\u20131125.e1110 (2017).","journal-title":"Cell"},{"key":"60057_CR31","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aai8711","volume":"9","author":"CE Mire","year":"2017","unstructured":"Mire, C. E. et al. Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody. Sci. Transl. Med. 9, eaai8711 (2017).","journal-title":"Sci. Transl. Med."},{"key":"60057_CR32","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/j.cell.2015.01.041","volume":"160","author":"T Hashiguchi","year":"2015","unstructured":"Hashiguchi, T. et al. Structural basis for Marburg virus neutralization by a cross-reactive human antibody. Cell 160, 904\u2013912 (2015).","journal-title":"Cell"},{"key":"60057_CR33","doi-asserted-by":"publisher","first-page":"e1005016","DOI":"10.1371\/journal.ppat.1005016","volume":"11","author":"ML Fusco","year":"2015","unstructured":"Fusco, M. L. et al. Protective mAbs and Cross-Reactive mAbs Raised by Immunization with Engineered Marburg Virus GPs. PLoS Pathog. 11, e1005016 (2015).","journal-title":"PLoS Pathog."},{"key":"60057_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1038\/s41564-018-0157-z","volume":"3","author":"AI Flyak","year":"2018","unstructured":"Flyak, A. I. et al. Broadly neutralizing antibodies from human survivors target a conserved site in the Ebola virus glycoprotein HR2-MPER region. Nat. Microbiol. 3, 670\u2013677 (2018).","journal-title":"Nat. Microbiol."},{"key":"60057_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.coi.2022.102234","volume":"78","author":"C Britto","year":"2022","unstructured":"Britto, C. & Alter, G. The next frontier in vaccine design: blending immune correlates of protection into rational vaccine design. Curr. Opin. Immunol. 78, 102234 (2022).","journal-title":"Curr. Opin. Immunol."},{"key":"60057_CR36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.24272\/j.issn.2095-8137.2017.054","volume":"39","author":"G Wong","year":"2018","unstructured":"Wong, G. et al. Development and characterization of a guinea pig model for Marburg virus. Zool. Res. 39, 32\u201341 (2018).","journal-title":"Zool. Res"},{"key":"60057_CR37","doi-asserted-by":"publisher","first-page":"S258","DOI":"10.1093\/infdis\/jiv182","volume":"212","author":"RW Cross","year":"2015","unstructured":"Cross, R. W. et al. Comparison of the pathogenesis of the Angola and Ravn strains of Marburg virus in the outbred guinea pig model. J. Infect. Dis. 212, S258\u2013S270 (2015).","journal-title":"J. Infect. Dis."},{"key":"60057_CR38","doi-asserted-by":"publisher","first-page":"eabj0299","DOI":"10.1126\/science.abj0299","volume":"373","author":"KS Corbett","year":"2021","unstructured":"Corbett, K. S. et al. Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. Science 373, eabj0299 (2021).","journal-title":"Science"},{"key":"60057_CR39","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.1084\/jem.20170161","volume":"214","author":"SW Stonier","year":"2017","unstructured":"Stonier, S. W. et al. Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses. J. Exp. Med. 214, 2563\u20132572 (2017).","journal-title":"J. Exp. Med."},{"key":"60057_CR40","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1128\/CVI.00107-16","volume":"23","author":"M Natesan","year":"2016","unstructured":"Natesan, M. et al. Human Survivors of Disease Outbreaks Caused by Ebola or Marburg Virus Exhibit Cross-Reactive and Long-Lived Antibody Responses. Clin. Vaccin. Immunol. 23, 717\u2013724 (2016).","journal-title":"Clin. Vaccin. Immunol."},{"key":"60057_CR41","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1038\/s42003-022-03767-1","volume":"5","author":"W Peng","year":"2022","unstructured":"Peng, W. et al. Glycan shield of the ebolavirus envelope glycoprotein GP. Commun. Biol. 5, 785 (2022).","journal-title":"Commun. Biol."},{"key":"60057_CR42","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3390\/v4040447","volume":"4","author":"S Bale","year":"2012","unstructured":"Bale, S. et al. Structural basis for differential neutralization of ebolaviruses. Viruses 4, 447\u2013470 (2012).","journal-title":"Viruses"},{"key":"60057_CR43","doi-asserted-by":"publisher","first-page":"11931","DOI":"10.1073\/pnas.1609316113","volume":"113","author":"W He","year":"2016","unstructured":"He, W. et al. Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus. Proc. Natl. Acad. Sci. USA 113, 11931\u201311936 (2016).","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"60057_CR44","doi-asserted-by":"publisher","first-page":"e01865","DOI":"10.1128\/JVI.01865-18","volume":"93","author":"R Keshwara","year":"2019","unstructured":"Keshwara, R. et al. A recombinant rabies virus expressing the Marburg virus glycoprotein is dependent upon antibody-mediated cellular cytotoxicity for protection against Marburg virus disease in a murine model. J. Virol. 93, e01865\u201301818 (2019).","journal-title":"J. Virol."},{"key":"60057_CR45","doi-asserted-by":"publisher","first-page":"1790","DOI":"10.1016\/j.ymthe.2024.04.019","volume":"32","author":"B Montoya","year":"2024","unstructured":"Montoya, B. et al. mRNA-LNP vaccine-induced CD8(+) T cells protect mice from lethal SARS-CoV-2 infection in the absence of specific antibodies. Mol. Ther. 32, 1790\u20131804 (2024).","journal-title":"Mol. Ther."},{"key":"60057_CR46","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/s41590-022-01163-9","volume":"23","author":"C Li","year":"2022","unstructured":"Li, C. et al. Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine. Nat. Immunol. 23, 543\u2013555 (2022).","journal-title":"Nat. Immunol."},{"key":"60057_CR47","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","volume":"53","author":"D Laczko","year":"2020","unstructured":"Laczko, D. et al. A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice. Immunity 53, 724\u2013732.e727 (2020).","journal-title":"Immunity"},{"key":"60057_CR48","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.tube.2004.08.001","volume":"85","author":"IM Orme","year":"2005","unstructured":"Orme, I. M. Mouse and guinea pig models for testing new tuberculosis vaccines. Tuberculosis 85, 13\u201317 (2005).","journal-title":"Tuberculosis"},{"key":"60057_CR49","doi-asserted-by":"publisher","first-page":"e39298","DOI":"10.1371\/journal.pone.0039298","volume":"7","author":"Y Guo","year":"2012","unstructured":"Guo, Y. et al. Immunoglobulin genomics in the guinea pig (Cavia porcellus). PLoS One 7, e39298 (2012).","journal-title":"PLoS One"},{"key":"60057_CR50","doi-asserted-by":"publisher","first-page":"e0208977","DOI":"10.1371\/journal.pone.0208977","volume":"13","author":"S Matsuzawa","year":"2018","unstructured":"Matsuzawa, S., Isobe, M. & Kurosawa, N. Guinea pig immunoglobulin VH and VL naive repertoire analysis. PLoS One 13, e0208977 (2018).","journal-title":"PLoS One"},{"key":"60057_CR51","doi-asserted-by":"publisher","first-page":"672","DOI":"10.3389\/fmicb.2019.00672","volume":"10","author":"L Lei","year":"2019","unstructured":"Lei, L. et al. Antigen-specific single B cell sorting and monoclonal antibody cloning in guinea pigs. Front Microbiol 10, 672 (2019).","journal-title":"Front Microbiol"},{"key":"60057_CR52","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01478-23","volume":"98","author":"MJ Vukovich","year":"2024","unstructured":"Vukovich, M. J. et al. Development of LIBRA-seq for the guinea pig model system as a tool for the evaluation of antibody responses to multivalent HIV-1 vaccines. J. Virol. 98, e0147823 (2024).","journal-title":"J. Virol."},{"key":"60057_CR53","doi-asserted-by":"crossref","unstructured":"Hevey, M., Negley, D., Staley, A. & Schmaljohn, A. Determination of vaccine components required for protecting cynomolgus macaques against genotypically divergent isolates of Marburg virus. 20th Annual Meeting of the American Society for Virology. Abstract W36\u20134 (2001).","DOI":"10.1016\/S0264-410X(01)00353-X"},{"key":"60057_CR54","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1016\/S0264-410X(01)00353-X","volume":"20","author":"M Hevey","year":"2001","unstructured":"Hevey, M. et al. Marburg virus vaccines: comparing classical and new approaches. Vaccine 20, 586\u2013593 (2001).","journal-title":"Vaccine"},{"key":"60057_CR55","doi-asserted-by":"publisher","first-page":"9659","DOI":"10.1128\/JVI.00959-06","volume":"80","author":"KM Daddario-DiCaprio","year":"2006","unstructured":"Daddario-DiCaprio, K. M. et al. Cross-protection against Marburg virus strains by using a live, attenuated recombinant vaccine. J. Virol. 80, 9659\u20139666 (2006).","journal-title":"J. Virol."},{"key":"60057_CR56","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1038\/nrd4278","volume":"13","author":"U Sahin","year":"2014","unstructured":"Sahin, U., Kariko, K. & Tureci, O. mRNA-based therapeutics-developing a new class of drugs. Nat. Rev. Drug Discov. 13, 759\u2013780 (2014).","journal-title":"Nat. Rev. Drug Discov."},{"key":"60057_CR57","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1128\/JVI.00069-06","volume":"80","author":"JS Towner","year":"2006","unstructured":"Towner, J. S. et al. Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. J. Virol. 80, 6497\u20136516 (2006).","journal-title":"J. Virol."},{"key":"60057_CR58","doi-asserted-by":"crossref","unstructured":"Johnson, E. D. et al. Characterization of a new Marburg virus isolated from a 1987 fatal case in Kenya. Arch. Virol. Suppl. 11, 101\u2013114 (1996).","DOI":"10.1007\/978-3-7091-7482-1_10"},{"key":"60057_CR59","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1016\/j.celrep.2018.07.044","volume":"24","author":"M Meyer","year":"2018","unstructured":"Meyer, M. et al. Antibody repertoires to the same ebola vaccine antigen are differentially affected by vaccine vectors. Cell Rep. 24, 1816\u20131829 (2018).","journal-title":"Cell Rep."},{"key":"60057_CR60","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","volume":"366","author":"ME Ackerman","year":"2011","unstructured":"Ackerman, M. E. et al. A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples. J. Immunol. Methods 366, 8\u201319 (2011).","journal-title":"J. Immunol. Methods"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60057-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60057-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T09:09:40Z","timestamp":1751360980000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-025-60057-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":60,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["60057"],"URL":"https:\/\/doi.org\/10.1038\/s41467-025-60057-0","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4087897\/v1","asserted-by":"object"}]},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"assertion":[{"value":"12 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"S.H. and A.C. are employees of Moderna. J.E.C. Jr. has served as a consultant for Luna Labs USA, Merck Sharp & Dohme Corporation, Emergent Biosolutions, and BTG International Inc. and is a member of the scientific advisory board of Meissa Vaccines, a former member of the scientific advisory board of GigaGen (Grifols), and is a founder of IDBiologics. J.E.C, Jr\u2019s laboratory received unrelated sponsored research agreements from AstraZeneca, Takeda Vaccines, and IDBiologics. A.B. is a co-founder and vice-president of Emervax, Inc. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5702"}}